Immunicum AB (publ) Receives FDA Fast Track Designation for Ilixadencel in Gastrointestinal Stromal Tumors (GIST)

What we doOur approachPipelineTechnologyPublications
About usExecutive ManagementBoard of DirectorsScientific Advisory Board
News & eventsPress releasesEventsInterviews
Investors
Careers

Back
Immunicum AB (publ) Receives FDA Fast Track Designation for Ilixadencel in Gastrointestinal Stromal Tumors (GIST)
 8:00:00 AM

Keep reading
Immunicum AB (publ) Announces Upcoming Virtual Investor Event on December 9thRead